NEW YORK (Bloomberg) — Bermuda-based pharmaceutical company Warner Chilcott Ltd. settled lawsuits it brought to stop Watson Pharmaceuticals Inc. from making generic versions of the Loestrin birth-control pill and the Femcon FE chewable birth-control pill.

Under the settlement announced by both companies in a joint statement, Corona, California-based Watson will license the Loestrin patents and be able to enter the market either in January 2014 or when another generic copy is produced.

Warner Chilcott will allow Watson to enter the market with a Femcon generic within 180 days after Teva Pharmaceutical Industries Ltd.'s Barr Laboratories unit begins selling a generic version in January 2013, according to the statement. The companies didn't offer any further settlement details.